Biolinq Secures $58 Million for Development of World’s Smallest Biosensor

San Diego-based company Biolinq has secured a whopping $58 million in funding, bringing its total funding to an impressive $178 million. The company, founded in 2012, is making waves in the biosensor world with its innovative wearable patch that measures glucose levels from the intradermal space just beneath the skin’s surface.

CEO Rich Yang explained that the patch leverages electrochemical sensors in the papillary dermis, the top layer of skin beneath the outermost layer. This location is ideal for sensing biomarkers as it is highly metabolically active without causing pain or bleeding. Biolinq’s technology, which includes multiple tiny microsensors on a small silicon chip, is the smallest biosensor in the world.

What sets Biolinq apart from its competitors is its real-time feedback display directly on the device, eliminating the need for a smartphone app. This feature allows users to see immediate changes in their glucose levels and make informed decisions about their health in the moment.

With the new funding, Biolinq plans to complete a pivotal clinical trial in the U.S. this year and seek FDA clearance for its device. The company’s groundbreaking technology has the potential to revolutionize the way individuals monitor their glucose levels and make informed decisions about their health in real-time.